MDT

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+0.83%

Status

scored

Maintain MDT at 3-5% portfolio weight with anchored $85.55 daily-close as an active decision point rather than a hard stop; retain the 3.37% dividend carry and reject puts inside the defended $84.50-$87.75 support cluster at the 200 SMA. Scale to 6-7% ONLY on confirmed close above $89.46 (50 SMA) with volume ≥80M followed by pullback to $88.50-$89.00, or to 7-9% ONLY on confirmed close below $84.50 with volume ≥90M and 3-5 day basing at $82-$84, with maximum exposure capped at 7% in either direction. Q2 FY27 earnings in late October is the mandatory binary re-evaluation with explicit bull/base/bear decision tree.

Outcome

✗

Return

+2.62%

Status

scored

Maintain Underweight on MDT with a 30-35% trim executed at market (~$85.51), reducing to 65-70% of benchmark weight, anchored by a $82.00 daily-close stop on retained core exposure. Fresh short initiation is deferred to a confirmed rejected retest of the 50 SMA at $89.45, sized at 12.5% of healthcare allocation with a $90.50 stop. The Q2 FY27 earnings print in mid-November serves as the binary re-evaluation catalyst, with downgrade to Sell triggered on confirmed daily close below $82 on volume exceeding 12M or material earnings miss.

Outcome

✓

Return

-1.81%

Status

scored

Trim MDT by 30-35% at market (~$88.50) to reduce to 65-70% of benchmark weight, anchored by a $87.00 daily-close stop (200 SMA breach on rising volume = full exit). The synthesis rejects the trader's full Sell (47-year Aristocrat with 1.5x FCF coverage still warrants core exposure) and the Conservative's hold (5 sessions of escalating distribution 26.6M→52.1M IS the confirmation signal). Re-entry requires either 10 EMA reclaim at $88.84 on ≥40M volume with MACD/RSI confirmations, or Q2 FY27 earnings validating $6.41 forward EPS with >+8% organic revenue growth and >19.5% operating margin.

Outcome

✓

Return

-1.00%

Status

scored

MDT receives an Underweight rating with a 20% trim executed at market (~$86.38), retaining 80% of the position as a core holding anchored to a $80.60 daily-close stop. A contingent 15% add-on trim is triggered automatically if price closes below $80.60 on volume exceeding 25M shares, bringing total exposure reduction to 35% if the support cluster fails on distribution. The $5.4B FCF, 47-year dividend Aristocrat streak, 13.7x forward P/E, and 3.33% dividend yield provide a genuine valuation floor that prevents a full Sell rating.

Outcome

✗

Return

+1.84%

Status

scored

Underweight rating maintained with a 35-40% trim at market (~$86), reducing position to 60-70% of benchmark weight while anchoring the retained core at a $84.00 daily-close stop. The trade rejects both the Hold trap (avoiding confirmation lag) and the Sell overshoot (ignoring the genuine 13.5x P/E valuation floor), instead executing a deterioration-adjusted trim that preserves the 3.3% dividend carry and Q2 FY27 optionality. No puts are purchased as the stop IS the hedge at a triple support confluence ($84-85 zone).

Outcome

✓

Return

-0.07%

Status

scored

Maintain Medtronic (MDT) exposure at current levels with a HOLD rating ahead of the Q2 FY27 catalyst in late November; the $80 hard stop (3.1 ATR below spot) anchors downside protection while the $89.07 (50 SMA) serves as the re-entry trigger on declining volume confirmation. The 26.6M share distribution session represents genuine bearish pressure, making a 10-15% trim advisable on failed retest of the 50 SMA rather than waiting for $92-93; any segment-level restructuring announcement (especially diabetes or CRM) triggers immediate reassessment given the $43.2B goodwill (86% of equity) with negative tangible book.

Outcome

–

Return

+0.17%

Status

scored

Trim MDT by 33% over 1-2 weeks moving to Underweight, executing into strength on any relief bounce toward the $88-$90.50 resistance confluence; if no bounce within 3-5 sessions, execute remaining at market. Anchor retained 67% core position at an $83.00 daily-close stop (August swing low zone, ~3.6% below entry). Q2 FY27 print in mid-November is the binary re-engagement catalyst — rebuild 15-20% if print exceeds +12% with technical confirmation, or exit remaining position if print is below +8% or shows margin compression.

Outcome

–

Return

-0.92%

Status

scored

MDT warrants an Underweight rating with a 30% trim executed at market (~$87.50) following confirmed breakdown below the 200 SMA on 3x average volume, retaining 70% core position anchored at a $92.00 daily-close stop. The decision balances the confirmed technical deterioration (death cross forming, MACD accelerating negative, sequential revenue decline) against a genuine quality floor (1.6x FCF dividend coverage, 47+ year dividend streak, 13.6x forward P/E, 65% gross margins) that prevents full exit, with re-engagement contingent on Q2 FY27 print validating or invalidating the growth narrative.

Outcome

✗

Return

-2.69%

Status

scored

All three analysts converge on HOLD, with the Neutral Analyst's tactical add/trim rules (25-33% sizing on confirmed 10 EMA reclaim or 200 SMA break) providing the correct execution framework through the binary Q2 FY27 catalyst in late October/early November. The structural floor ($8.82B cash, $5.41B TTM FCF, 47-year dividend streak) remains intact, making neither Underweight nor Overweight justified given deteriorating technicals and embedded heroic assumptions in forward P/E.

Outcome

✗

Return

+0.97%

Status

scored

Trim Medtronic 25% using a two-tranche architecture: ~12.5% at market in the $88.00–$88.50 zone and ~12.5% as a limit order at $89.00–$89.50 with a hard cancel after 3–5 sessions if unfilled. Anchor the retained 70–75% core with a $87.50 daily-close stop and cap total position at ≤2.5% of portfolio, with a mandatory 3-week mid-point reassessment ahead of Q2 FY27 results.

Outcome

–

Return

+0.15%

Status

scored

Trim 30-35% of MDT via pre-committed architecture—15-17% scaled into $89-92 resistance over 5-10 sessions, 15-18% contingent on bear trigger (confirmed close <$87.80 with volume >12M), with hard cancel-and-flatten if bull trigger fires (close >$93 on volume >12M with MACD histogram contracting); retain 65-70% core anchored by $86.00 daily-close stop, with re-evaluation at Q2 FY27 print (late November) and mandatory 3-week mid-point reassessment.

Outcome

✓

Return

-0.88%

Status

scored

Trim 20-25% of MDT (Medtronic) exposure given cumulative -2.2% to -3.2% alpha drag across four prior HOLDs, MACD histogram at -0.49 with 11-session deterioration, and Bollinger Band breach on 1.4x volume; retain 75-80% core to capture dividend carry and Q2 FY27 optionality. Execute 10-15% into the $89-91 bid zone over 3-5 sessions while avoiding the $0.33 SMA buffer, with a contingent 10% tranche on close below $87.80 and automatic cancel-and-flatten if close exceeds $89.50 with MACD confirmation.

Outcome

✗

Return

-1.62%

Status

scored

Maintain MDT at current weight with a HOLD rating as the research team converges on a defensive holding strategy rather than a tactical momentum play; the 3.14% dividend yield and 49-year dividend streak provide carry support while awaiting Q1 FY27 binary catalyst resolution. Key execution rules include a hard stop at $88.40 daily close, an add trigger requiring close above $89.50 with volume below 10M and RSI above 45 for two consecutive sessions, and an optional 15-25% trim on relief bounce to $92-$92.50 with contracting volume—designed to address the flat-alpha bleed that produced negative alpha on all three prior HOLD calls.

Outcome

✓

Return

-1.07%

Status

scored

Underweight rating maintained with a 25–30% trim of MDT exposure over 1–2 weeks, selling into the $92.50–$94.00 zone (10–15% now, 10–15% contingent). Retained core stops at $88.86 (50 SMA). New longs prohibited above $90 pending structural confirmation at lower bands. Mandatory 3-week mid-point reassessment with full review at Q2 FY27 print (late November). Protective put overlay at $88 strike, 2–3 month expiry recommended.

Outcome

✓

Return

-0.41%

Status

scored

Trim 10-15% of MDT exposure into the $91.50-$92.50 bid zone now, with the retained 85-90% core anchored by a structural stop at $88.30-$88.70 (50/200 SMA cluster). The $94 trim trigger has been tested three times without breaking, MACD has rolled over with widening negative histogram, and repeated Hold ratings produced cumulative -1.2% alpha bleed — mandating hard sizing action rather than another patience extension. Reserve dry powder for either confirmed close above $94.70 on >12M volume with MACD positive re-cross or a flush to $85-$87 with reversal confirmation.

Outcome

✓

Return

-0.69%

Status

scored

Maintain MDT at current weight to collect the 3.1% dividend carry while awaiting the Q2 FY27 catalyst, with existing holders doing nothing at $92.77 given failed $94 resistance tests and bearish MACD/RSI signals; new capital must wait for staged entry at $89-90 or $85-87 pullback zones rather than front-loading. A mandatory 3-week reassessment caps the patience window, with hard stop at $87.50 and trim/upgrade triggers at $87.50 and $94.70 respectively on confirmed volume.

Outcome

✓

Return

+0.18%

Status

scored

Maintain Medtronic (MDT) at current weight with ~$90 cost basis and 3%+ dividend yield; the bull/bear evidence is genuinely balanced with 7.9% organic growth on $37B offset by three failed $94.17 resistance tests and MACD bearish cross. Do not add between $90-$94.50 consolidation range—upside to target zones is 5-11% vs only 2.8% downside to $87.50 stop, violating asymmetric risk/reward. Upgrade to Overweight triggers at confirmed close above $94.70 on volume >12M with MACD positive cross; downgrade to Underweight triggers at close below $87.50 on volume >15M with 50/200 SMA break.

Outcome

–

Return

-1.23%

Status

scored

Maintain an Underweight rating on MDT with a phased trim strategy of 20-25% total exposure, executing 10-15% now into the $93-95 zone and reserving 5-10% contingent on a confirmed close below $92.00 with negative MACD or rejection at upper Bollinger on volume. Place the protective stop at $88.50-$89.00 (just below the 50/200 SMA cluster), with an ATR of $2.31 providing appropriate buffer. The Q2 FY27 print (late November) serves as the binary catalyst for medium-term reassessment, while the 4-6 week near-term horizon is framed by upcoming CPI (Sep 11) and FOMC (Sep 16) events.

Outcome

✓

Return

-0.05%

Status

scored

Maintain MDT position at $93.80 and collect the 3.17% dividend carry while awaiting the Q2 FY27 catalyst in late November. Execute a tiered trim by selling 15-20% of the position on a confirmed daily close above $96 with volume exceeding 10M, retaining 80-85% core exposure. The better add zone is $87-$89 ONLY with Q2 confirmation of 7-9% organic growth, no channel fill, and a MACD histogram flip back positive, with a hard stop at $89.50.

Outcome

✗

Return

+3.12%

Status

scored

Analysts recommend trimming 30-35% of Medtronic exposure on any rally into the $92.00-$93.50 zone with a hard abort at $95.00, while retaining a 65-70% core position sized to the 3.14% dividend carry. Technical deterioration is confirmed with the 50 SMA below the 200 SMA, MACD histogram at -0.40, and price below both the 10 EMA and VWAP, while the 14.2x forward P/E embeds ~57% EPS recovery that the 7.9% organic growth does not justify.

Outcome

✓

Return

-0.72%

Status

scored

Maintain the MDT position and collect the 3.13% dividend carry while awaiting the Q2 FY27 catalyst (~10 weeks out); fundamentals are genuinely improving but technical setup shows fading momentum with MACD bearish cross and failed $94.29 breakout, warranting HOLD rather than adding at current $91.62 price. Execute the pre-committed trigger ladder: hard stop at $87.00, modest add on confirmed hold of $87.45 with bullish MACD re-cross, and larger add on confirmed close above $94.29 on volume >10M.

Outcome

–

Return

-0.29%

Status

scored

Reduce MDT by trimming 20-30% of the position to lock in 29.7% rally gains from $73 to $94.72, while retaining a 70-80% core position to capture the 3.12% dividend yield. Hard stop set at $87.00 (just below 50 SMA at $87.18 and 200 SMA at $88.61 cluster), with pre-committed entry triggers for a potential flush to $84-87 with basing pattern (Tranche A) or a confirmed close above $94.31 with MACD turning up on volume >10M (Tranche B). The Underweight rating reflects a failed breakout at $94.31 confirmed by MACD losing 44% of upside thrust and RSI reset from 75 overbought to 55, with binary Q2 FY27 earnings ahead creating asymmetric risk.

Outcome

–

Return

-0.54%

Status

scored

Maintain Overweight on MDT based on strong fundamentals (14.4x forward P/E, 13.7% organic growth, 3%+ yield, beat-and-raise Q1 FY27, $5.4B FCF), but do not initiate at the current $92.39 price due to the binding 9/4 lesson — the current setup of extended entry with fading momentum (negative MACD histogram, two failed resistance tests at $94/$95, RSI cooling from 75) matches the exact pattern that produced -1.9% raw/-1.3% alpha on September 4; instead, wait for TRIGGER A (pullback to $86.50-$88.00 zone at 50% weight, stop $85.00) or TRIGGER B (confirmed close above $95.51 on >10M volume at 40% weight, stop $91.70), with reversion to Hold if neither fires in 4-6 weeks.

Outcome

✗

Return

-1.89%

Status

scored

Analysts agree on the fundamental thesis but diverge on entry timing—Overweight rating reflects a calibrated three-tranche approach deploying ~0.6-0.75x benchmark weight immediately at $94, with hard stop at $89.50 and staged capital reserves for pullback ($91.70-$92.30) or breakout ($94.74) entries; Q2 FY27 earnings print (late Nov/early Dec 2026) will determine whether to upgrade to Buy or downgrade based on ablation growth trajectory and EPS estimate stability.

Outcome

✓

Return

+1.15%

Status

scored

Maintain MDT at HOLD with a tiered capital deployment framework rather than binary sizing. Deploy ~1/3 of intended new capital on the imminent 50/200 SMA golden cross as a structural starter, another 1/3–1/2 on either a breakout above $94.49 with rising volume OR a pullback to the $91.38–$91.78 Bollinger midline zone, and reserve the remainder for a flush to $88.67 or breakout retest. Hard stop sits at $86.45 (50 SMA), with Q2 FY27 earnings print as the decisive re-evaluation catalyst.

Outcome

–

Return

+1.00%

Status

scored

Initiate an Overweight position on Medtronic with a staged two-thirds/one-third approach, buying initial weakness in the $88.00–$90.50 zone while reserving capital to add on flush to $85–$87 or Q2 FY27 confirmation. Set hard stop at $83.90, trim 25% on retest of $94.72–$95.21, and formal reassess after Q2 FY27 print with $95 price target.

Outcome

✓

Return

+0.15%

Status

scored

Maintain MDT with structured patience through Q2 FY27 print rather than upgrading to aggressive positioning or retreating defensively. Add 3-5% only on confirmed triggers (breakout above $95.29 on declining volume, or pullback to $90.46-$91.34 with positive MACD divergence), with 15-25% trim if stock stalls at $96-$97 without follow-through. Hard stop at $88.69 (200 SMA), with 3-4 week reassessment window if neither trigger fires; the 3.16% dividend yield anchors the position while catalysts resolve.

Outcome

✗

Return

+1.53%

Status

scored

Analyst consensus favors a 30% trim of MDT via laddered execution into the Q1 FY27 binary catalyst, citing negative asymmetry from bearish technical signals (price below 10 EMA at $91.19, MACD histogram at -0.37), 72% Polymarket hike probability, and ~50% international revenue exposure to dollar strength. The Underweight rating over Hold is justified by the 8/19 lesson that defensive signal clusters resolve via drift toward catalysts, while avoiding full exit due to attractive fundamentals including 14x forward P/E, 1.28x FCF coverage, and 3.16% dividend yield providing carry through the window.

Outcome

✓

Return

-0.64%

Status

scored

Maintain core MDT position while trimming 10-15% ahead of Q1 FY27 earnings to reduce binary event exposure, using a trailing reference at $84.50 rather than a hard stop for post-print execution flexibility; re-enter on weakness into the $85-87 zone or on confirmed beat-and-raise with constructive guidance. The 3.2% dividend yield provides an income floor while the catalyst resolves over the 4-6 week window.

Outcome

✗

Return

+1.40%

Status

scored

Maintain MDT exposure with a Hold rating as three risk analysts converged on this stance despite disagreements on execution discipline. Pre-commit to two add triggers: a partial add (25-50% of intended size) if MDT breaks above $96 post-earnings with strong volume and follow-through, or a full incremental add on a $84-86 flush provided the forward EPS trajectory remains intact. Hard stop is set at $83, with a trim trigger at $98-100 absent fundamental confirmation, and a modest put/collar overlay recommended through the Q1 FY27/Jackson Hole catalyst window.

Outcome

✗

Return

-2.23%

Status

scored

MDT earns an OVERWEIGHT rating with staged execution, deploying a 33% starter position in the $90.50-$92.50 zone via limit orders. The structural case (14.4x forward P/E, 200 SMA turn, 3.16% yield, accelerating revenue) supports constructive positioning, but MACD warning, double top resistance, and binary Q1 FY27 catalyst warrant calibrated sizing rather than full conviction. Hard stop at $83.50, with tighter add conditions (200 SMA hold + MACD positive at $87; volume-confirmed breakout at $94.50) and a 30-day time stop if neither trigger fires.

Outcome

✓

Return

+0.97%

Status

scored

Maintain Medtronic as a Hold with a 4-6 week horizon through Q1 FY27 print. Do not add at current $91 level due to technical exhaustion signals (five lower highs, MACD compression, bearish candle below 10 EMA); do not trim below $94 resistance. Pre-committed staged trim 15-20% on initial $94 test, additional 10% on confirmed close above $96, with hard stop at $86.50. Scale-in add trigger at $89.50-$90.90 on RSI reset below 60 with volume exceeding 5M. Binary catalyst framework hinges on Q1 FY27 revenue ≥5% YoY plus normalized tax guidance to upgrade, versus revenue below 3% YoY or forward EPS cut exceeding 5% to downgrade.

Outcome

✗

Return

-1.89%

Status

scored

Maintain MDT at or below benchmark weight rather than adding at $92.90, with staged entry at one-half size on a confirmed $89-$91 pullback (10 EMA + 20 SMA confluence, RSI reset below 60, volume exceeding 5M) to capture asymmetric upside if the earnings bridge to $5.00-$5.30 EPS is credibly demonstrated; anchor price target to $93.50 (current print) and pre-commit to mechanical trim triggers at $97-$100 with a $87 hard stop on a closing basis over a 4-6 week horizon.

Outcome

✓

Return

-0.48%

Status

scored

Hold MDT at current exposure without adding or trimming at ~$93, which sits in the neutral no-man's-land between the BUY zone ($88.50–$90.00) and TRIM zone ($97.50–$100). Pre-committed mechanical triggers govern all action: scale in 50–75 bps on a test of $88.50–$90.00 with RSI reset <60 and volume >5M; trim 25–33% into $97.50–$100 with confirmed bearish reaction; exit on close below $87.50.

Outcome

–

Return

+1.14%

Status

scored

Trim Medtronic (MDT) by 10-15% given an extreme 3.4σ extension above the 50-day SMA, upper Bollinger rejection, volume divergence, and fragile macro backdrop (Walmart miss, weak retail, 86% no-cut pricing). Execute 10% trim immediately at $92, with optional additional 5% trim if price reaches $94 upper Bollinger. The 8/19 lesson is dispositive: a small defensive trim (10-15%) is the calibrated response on low-beta compounders with binary catalysts ahead at reduced cap, rather than binary Hold/Add. Maintain $87.80 hard stop and preserve position for Q1 FY27 catalyst with mechanical upgrade/downgrade triggers.

Outcome

✗

Return

-1.94%

Status

scored

Maintain MDT at 2.5% portfolio cap without adding at $94+; the position is already pre-sized smaller, so further trimming would repeat the 8/14 alpha-bleed error. Re-engage via two mechanical scale-in triggers at $90.50–$91.50 and $88.50–$89.00 with specific technical conditions, with hard stop at $87.70 on new adds. Pre-commit to FY27 Q1 print binary decision framework with upgrade thresholds (revenue ≥5% YoY + Affera traction + raised FY27 guide ≥5%) and downgrade triggers (revenue <3% YoY OR EPS cut >5% OR material litigation reserve).

Outcome

✗

Return

+2.22%

Status

scored

Maintain MDT at 2.5% portfolio cap (lower bound of plan range) with HOLD rating—the technical setup is stretched (RSI 71.03, declining volume at resistance) and binary catalyst is 4-6 weeks away, making current levels a low-reward, higher-risk profile; do not add at $92.09, instead pre-commit to re-engagement triggers at $89.70-$88.55 pullback (RSI <60, volume >5M) or confirmed 2-3 day close above $93.50 (volume >7M) before adding 0.75% and 0.50-0.75% respectively, with stops at $85.50-$86.00 for new adds and $83.43 trailing stop on existing core.

Outcome

✗

Return

+1.64%

Status

scored

Maintain Medtronic at market weight with a Hold rating as the $90.60 level is too extended for new capital; stage entries at $88.50–$89.20 with volume confirmation (>5M shares) and RSI reset below 60, with hard stop at $80.60. The late August/early September FY27 Q1 print serves as a binary catalyst with mechanical thresholds: upgrade to Overweight if revenue ≥5% YoY plus Affera traction plus FY27 organic guide ≥5%; downgrade to Underweight with 15–25% trim if revenue <3%, EPS revised down >5%, or litigation reserve build. Consider covered calls at $92–95 strikes expiring post-print to monetize ~26% implied vol and lift annualized yield toward 4.5%.

Outcome

–

Return

-0.73%

Status

scored

Trim Medtronic (MDT) by 15–25% at the $92–93 Bollinger upper band rather than the proposed 30–50%, guided by prior 8/10, 8/12, and 8/13 decision log lessons that rule out aggressive trimming on defensive compounders at 200 SMA reclaim; maintain $87.50 hard stop (below 200 SMA at $88.56) while retaining the majority of the position given real fundamental inflection ($9.81B revenue +9.9% YoY, $4.625B TTM FCF) and favorable macro backdrop (85% no-cut odds). Three symmetric re-entry triggers: (a) pullback to 50 SMA at $82–84 with volume confirmation, (b) sustained close above $92.38 on >8M volume for 2+ sessions, or (c) FY27 Q1 earnings confirmation; optional $92–95 covered call overlay to boost annualized yield from 3.18% toward ~4.5%.

Outcome

✗

Return

+0.76%

Status

scored

The Portfolio Manager assigns an Underweight rating, recommending a measured 15–25% trim of MDT exposure ahead of the FY27 Q1 earnings print, smaller than the trader's proposed 30–50%, while maintaining a $87.50 hard stop-loss. The decision synthesizes the aggressive analyst's valuation gap thesis (14.1x forward P/E vs. 17–22x peer band), the conservative analyst's technical exhaustion signals (RSI 69.56, Bollinger rejection at $91.61, MACD tick-down), and the neutral analyst's caution on over-aggressive trimming, implementing lessons from prior decision logs that warn against trimming 30–50% into strength at a 200 SMA reclaim on defensive compounders while also requiring smaller pre-print sizing for binary catalysts.

Outcome

✓

Return

-0.20%

Status

scored

Maintain MDT at 5% portfolio cap for the 6-7% total shareholder yield carry (3.18% dividend plus ~3% buyback) rather than adding at $90.76, where overbought RSI (70.48), a barely-reclaimed declining 200 SMA, and a binary FY27 Q1 catalyst four trading days away create asymmetric risk; scale to 7-8% post-print on confirmation or hold through the earnings event with a hard stop at $88.56.

Outcome

–

Return

+0.09%

Status

scored

Analyst consensus favors an Overweight rating on MDT, initiating 50% of the target position at $90.68 to capture the 200 SMA reclaim as a regime-shift signal, while reserving 50% for adds on a pullback to the $87–88 confluence zone. A hard stop at $86.00 protects against a failed breakout, with trim levels at $95–96 and $100–103 to monetize the structural rerating, and a full rebalance trigger at $93 on above-10M volume.

Outcome

✗

Return

+1.42%

Status

scored

MDT is rated Underweight with a trim to ~75% of model weight due to unfavorable risk/reward at $89.41 — the bull's own downside scenario implies 22% downside ($70 vs $89.41 entry), volume is 18% below the 8M confirmation threshold, and price sits just 24¢ from the upper Bollinger band. The decision preserves exposure for re-engagement on confirmed breakout while monetizing elevated implied vol via a $92-95 covered call, maintaining a $88.58 hard stop.

Outcome

✗

Return

+2.58%

Status

scored

Maintain MDT at HOLD with a $93 price target and $82.75 trailing stop (2x ATR), avoiding additions at $87 as the stock trades $1.44 below the declining 200 SMA ($88.60) and MACD histogram has compressed 76% from July peak. The $90 covered call overlay monetizes resistance during the consolidation window ahead of the August/September FY27 Q1 earnings catalyst, with a 33% add trigger on confirmed daily close above $89 on volume expansion.